Charmacy Pharmaceutical Co., Ltd.
Symbol: 2289.HK
HKSE
10.6
HKDTržní cena dnes
26.6977
Poměr P/E
-2.4737
Poměr PEG
1.14B
MRK Cap
- 0.07%
Výnos DIV
Charmacy Pharmaceutical Co., Ltd. (2289-HK) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2048.73 | 634.2 | 503.8 | 641.8 | |||||||||||
balance-sheet.row.short-term-investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.net-receivables | 3455.49 | 965.4 | 865.3 | 731.3 | |||||||||||
balance-sheet.row.inventory | 2642.09 | 775.8 | 586.9 | 509.2 | |||||||||||
balance-sheet.row.other-current-assets | 1683.13 | 436.6 | 506.4 | 356 | |||||||||||
balance-sheet.row.total-current-assets | 9829.44 | 2812 | 2462.4 | 2238.2 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 1267.58 | 328.5 | 294.1 | 348.4 | |||||||||||
balance-sheet.row.goodwill | 24.1 | 6 | 6 | 6 | |||||||||||
balance-sheet.row.intangible-assets | 376.24 | 76.7 | 80.9 | 143 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 400.34 | 82.7 | 86.9 | 149.1 | |||||||||||
balance-sheet.row.long-term-investments | 1234.74 | 0 | 374.7 | 489.3 | |||||||||||
balance-sheet.row.tax-assets | 29.25 | 7.4 | 6.2 | 8.2 | |||||||||||
balance-sheet.row.other-non-current-assets | -1239.64 | 17 | -381 | -497.5 | |||||||||||
balance-sheet.row.total-non-current-assets | 1692.27 | 435.7 | 381 | 497.5 | |||||||||||
balance-sheet.row.other-assets | 71.28 | 0 | 22.6 | 27.4 | |||||||||||
balance-sheet.row.total-assets | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.account-payables | 3709.65 | 659.1 | 876.8 | 809.8 | |||||||||||
balance-sheet.row.short-term-debt | 5654.1 | 1531.1 | 1390 | 1512.6 | |||||||||||
balance-sheet.row.tax-payables | 296.21 | 56 | 94.2 | 44.6 | |||||||||||
balance-sheet.row.long-term-debt-total | 131.02 | 30.4 | 15.8 | 86.9 | |||||||||||
Deferred Revenue Non Current | -1.37 | -0.6 | 0 | 0.3 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.52 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 3492.36 | 2.5 | 1378.8 | 1349.2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 132.52 | 31 | 15.8 | 86.9 | |||||||||||
balance-sheet.row.other-liabilities | 11.38 | 0 | 0 | 13.2 | |||||||||||
balance-sheet.row.capital-lease-obligations | 84.83 | 37 | 15.8 | 15.5 | |||||||||||
balance-sheet.row.total-liab | 9303.15 | 2649.8 | 2271.4 | 2259 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 432 | 108 | 108 | 108 | |||||||||||
balance-sheet.row.retained-earnings | 712.22 | 181.2 | 207.5 | 117.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 280.97 | 279 | 1 | 1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 864.66 | 29.7 | 278 | 278 | |||||||||||
balance-sheet.row.total-stockholders-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 11593 | 3247.7 | 2865.9 | 2763.1 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 2289.85 | 597.8 | 594.5 | 504.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 11593 | - | - | - | |||||||||||
Total Investments | 33.27 | 0 | 11.1 | 11.6 | |||||||||||
balance-sheet.row.total-debt | 5796.4 | 1561.5 | 1405.8 | 1611.9 | |||||||||||
balance-sheet.row.net-debt | 3780.94 | 927.3 | 913.1 | 981.8 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 141.73 | 90.4 | 23.2 | 40.6 | ||||||||||
cash-flows.row.depreciation-and-amortization | 41.75 | 28.8 | 32 | 24.6 | ||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.change-in-working-capital | -404.55 | -300.2 | 20.9 | -227.9 | ||||||||||
cash-flows.row.account-receivables | -187.1 | -222.5 | -54.8 | -158 | ||||||||||
cash-flows.row.inventory | -217.45 | -77.7 | 75.8 | -69.8 | ||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-non-cash-items | 36.34 | 225 | -95.7 | 293.8 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -184.73 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | -2.9 | ||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 160.41 | 80.4 | 0.6 | 0.1 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 121.65 | 71.8 | -24.4 | -54.8 | ||||||||||
cash-flows.row.debt-repayment | 0 | -1074.5 | -824.1 | -888.6 | ||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | -40.42 | -28.4 | -52.5 | -56.5 | ||||||||||
cash-flows.row.other-financing-activites | 52.15 | 911.7 | 951 | 942.5 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 11.73 | -191.2 | 74.4 | -2.7 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -51.31 | -75.4 | 30.5 | 73.6 | ||||||||||
cash-flows.row.cash-at-end-of-period | 332.42 | 68.9 | 144.2 | 113.8 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 383.73 | 144.2 | 113.8 | 40.1 | ||||||||||
cash-flows.row.operating-cash-flow | -184.73 | 44.1 | -19.5 | 131.1 | ||||||||||
cash-flows.row.capital-expenditure | -38.77 | -8.6 | -25 | -52 | ||||||||||
cash-flows.row.free-cash-flow | -223.5 | 35.5 | -44.6 | 79.1 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 8578.91 | 4403.6 | 4175.3 | 3793.6 | |||||||||||
income-statement-row.row.cost-of-revenue | 8017.56 | 4110.9 | 3906.7 | 3559.5 | |||||||||||
income-statement-row.row.gross-profit | 561.35 | 292.7 | 268.6 | 234.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 97.18 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.operating-expenses | 304.92 | 178 | 116.1 | 163.4 | |||||||||||
income-statement-row.row.cost-and-expenses | 8322.48 | 4288.9 | 4022.8 | 3722.9 | |||||||||||
income-statement-row.row.interest-income | 66.96 | 4.3 | 30.5 | 37.7 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 235.39 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.1 | -0.4 | -0.1 | |||||||||||
income-statement-row.row.total-operating-expenses | -12.61 | -41.2 | 28.6 | -41.4 | |||||||||||
income-statement-row.row.interest-expense | 0 | 40.8 | 35.1 | 41.5 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 53.79 | 26.5 | 25.7 | 29.1 | |||||||||||
income-statement-row.row.ebitda-caps | 255.88 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 202.09 | 66.2 | 93.5 | 74.4 | |||||||||||
income-statement-row.row.income-before-tax | 189.47 | 67.4 | 122.1 | 33 | |||||||||||
income-statement-row.row.income-tax-expense | 47.75 | 16.1 | 31.7 | 9.8 | |||||||||||
income-statement-row.row.net-income | 141.73 | 51.3 | 90.5 | 23.2 |
Často kladené otázky
Co je Charmacy Pharmaceutical Co., Ltd. (2289.HK) celková aktiva?
Charmacy Pharmaceutical Co., Ltd. (2289.HK) celková aktiva jsou 3247655876.000.
Jaký je roční obrat podniku?
Roční příjmy jsou 4403633477.000.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.066.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -2.398.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je 0.012.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou 0.025.
Co je Charmacy Pharmaceutical Co., Ltd. (2289.HK) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 51344725.000.
Jaký je celkový dluh podniku?
Celkový dluh je 1561459369.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 178011533.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 634197229.000.